Credit Suisse said investors are overlooking Merck's PH III osteoporosis drug odanacatib. The firm raised tis 2020 estimate for the drug to $1.1B from $350B and expects increased focus on it with 2 interim efficacy reports expected this year. Shares are Outperform rated with a $45 price target, up from $44.
Stocks fell in a volatile session on Wednesday, with losses accelerating after Federal Reserve Chairman Ben Bernanke …